企業を読み込み中
Keep exploring
The themes Vertex Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The themes it is part of
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$47.6BA+
EXELExelixis, Inc.$16.8BA+
JAZZJazz Pharmaceuticals plc$15.5BA
TECHBIO-Techne Corp$11.4BA+
HALOHalozyme Therapeutics, Inc.$11.4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
GEHCGE Healthcare Technologies Inc.2026年10月28日CAGraded C, now A
どうやって稼いでいるか
- TRIKAFTA/KAFTRIO sales75%
- ALYFTREK sales17%
- KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI sales4%
- CASGEVY sales2%
- JOURNAVX sales2%
売上構成比はquarter ended June 30, 2026の推計であり、提出された報告書の数字ではありません。
競合
- bluebird bio
何を売っているか5
ALYFTREK
A once-daily combination medicine that improves the function of the faulty protein that causes cystic fibrosis.
TRIKAFTA/KAFTRIO
A combination medicine that improves the function of the faulty protein that causes cystic fibrosis. TRIKAFTA and KAFTRIO are brand names used in different markets.
KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI
Other medicines for cystic fibrosis that improve the function of the protein involved in the disease.
さらに2件を表示
CASGEVY
A gene-editing treatment for severe sickle cell disease and transfusion-dependent beta thalassemia. A patient's blood-forming cells are collected, edited at a manufacturing facility, and returned for infusion.
JOURNAVX
An oral, non-opioid medicine for moderate-to-severe acute pain in adults.
誰が買っているか5
- Specialty pharmacies and specialist distributors buy Vertex medicines and resell them to patients, pharmacies, health care providers, hospitals, or treatment centers.
- Major wholesalers in the United States buy Vertex medicines for resale through pharmacies and health care providers.
- Outside the United States, distributors, retail pharmacies, hospitals, and clinics buy or distribute medicines; some hospitals and clinics are government-owned or supported.
さらに2件を表示
- Authorized treatment centers can receive CASGEVY directly from Vertex in some markets.
- Government health programs and commercial insurers decide whether to cover medicines and reimburse purchases.
何に支えられ、何に崩されうるか
事業が頼っているもの
- 1The business depends substantially on cystic fibrosis medicines; sales therefore depend on continued patient use, access, and the medicines' ability to compete with other treatments.
- 2Vertex relies on outside manufacturers and suppliers for much of its commercial and clinical supply. CASGEVY also requires coordinated cell collection, editing, shipping, and treatment-center infusion.
- 3Sales depend on government programs and commercial insurers covering medicines and agreeing to reimbursement terms. The company also pays royalties on certain cystic fibrosis medicines and shares CASGEVY profits with CRISPR Therapeutics.
うまくいかなくなる可能性
- 1The company identifies its cystic fibrosis medicines as a substantial source of business dependence. Competing treatments, changes in patient use, or loss of patent protection could reduce sales.
- 2Vertex's future products depend on clinical trials showing acceptable safety and benefit and on regulators approving them. A delay or failure in programs such as povetacicept, inaxaplin, or zimislecel could limit its ability to add new medicines.
- 3The company relies on complex supply chains, outside manufacturers, and treatment-center coordination, particularly for cell and gene therapies. Manufacturing or distribution problems could delay or interrupt supply.
Vertex Pharmaceuticals Inc.について
Vertex discovers, tests, manufactures, and sells prescription medicines. Its approved medicines treat cystic fibrosis, severe sickle cell disease, transfusion-dependent beta thalassemia, and moderate-to-severe acute pain; it is also testing treatments for kidney disease, type 1 diabetes, and other conditions. It sells mainly through specialty pharmacies, distributors, and wholesalers, with some gene therapy supplied directly to treatment centers.
- 本社
- Boston, Massachusetts
- 設立
- 1989
- 従業員数
- 6,400 (December 31, 2025, high)
- 上場市場
- NASDAQ
- 決算期
- December 31
Vertex Pharmaceuticals Inc. 自身が米国証券取引委員会（SEC）に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。 これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。